Season's Savings | ₹5/mo for 3 months

₹199/month after first 3 months. Renews automatically. Terms apply.
Making it in Manufacturing cover art

Making it in Manufacturing

Making it in Manufacturing

Written by: ARTO Talent
Listen for free

About this listen

97% of our listeners don't realise they aren't followed, please double check, thank you!


Hosted by Thomas McMann, Making It In Manufacturing is ARTO's new in-person podcast series, spotlighting the leaders shaping the future of manufacturing, engineering and CDMOs in Life Sciences.


Each episode dives into the careers, decisions, and defining moments of industry mainstays - revealing the stories and insights behind real-world impact within the life science manufacturing and CDMO space.


If you're a leader in the space - or aspiring to be - this podcast is a must watch. The series is available on YouTube, Spotify, Apple Podcasts and all major platforms.

Hosted on Acast. See acast.com/privacy for more information.

ARTO Talent
Biological Sciences Careers Economics Hygiene & Healthy Living Personal Success Physical Illness & Disease Science
Episodes
  • CPHI Milan 2026: Molecule First, Patient Always - Chris Davison
    Nov 16 2026
    Register your interest for 2027 here: https://www.cphi.com/europe/register-attend/?utm_source=partner&utm_medium=referral&utm_campaign=hln27cpw-cl-artoCentrix Pharma Solutions helps biotech companies move from preclinical development into early stage clinical development. For CEO Chris Davison, that means the molecule first and the patient always: "we don't just make a product, we make medicines."This week on Making It In Manufacturing, Harry Sloan sat down with Chris Davison, CEO of Centrix Pharma Solutions, a small CDMO based in the UK, at CPHI Milan 2026, where ARTO was the official podcast partner.In this episode, Chris covers:(00:57) What Centrix does: formulation, analytical work and clinical manufacturing for biotech companies heading into the clinic, and what "Molecule First, Patient Always" means in practice.(02:23) His path to CEO: a pharmacist by training, 23 years at GSK in pharmaceutical development and leading CMC teams, then manufacturing supply chain and launches, before moving to Custom Pharmaceuticals and stepping up to lead the business.(04:03) Going from big pharma to a small company: wearing multiple hats, relying on your network, and not being afraid to ask for help.(05:16) Why now was the time to launch Centrix out of Custom Pharmaceuticals, a business that has been around for 47 years, and why it helps clients with what they need today and what they will need tomorrow.(07:23) Partnership, not transactions: challenging small biotechs on the consequences of their decisions down the line, so they make them with their eyes wide open.(09:41) The Integrated CMC Partnership with Sai Life Sciences and Agility Life Sciences, built to take the handoff out between drug substance and drug product.(12:28) Backing the growth plans: equipment that gives very rich data from small amounts of material, and an Innovate UK knowledge transfer partnership with the University of Sussex that brings a data scientist into the business.(15:05) What growth depends on: clients, the funding bar for biotech, and talent, with recent recruits from Brighton University, and why the people in a business drive its credibility.(18:12) How biotechs now choose a development partner: shorter runways, more selective, and wanting help to navigate their own journey rather than just a formulation and a batch.(19:09) Where AI fits at Centrix today: models to inform drug development, help in the quality functions with the human still at the centre, and empowering the workforce rather than replacing it.(21:40) What he wants Centrix to have delivered a year from now.Watch the full episode to hear why Chris wants more people to know what it really takes to develop a product.Follow ARTOLinkedIn: https://www.linkedin.com/company/artotalent/Spotify: https://open.spotify.com/show/1cSZVJ63yXJ3kqnVORyTbwInstagram: https://www.instagram.com/arto.talentTikTok: https://www.tiktok.com/@artotalentApple Podcasts: https://podcasts.apple.com/gb/podcast/making-it-in-manufacturing/id1819731245Website: https://arto-talent.com/Youtube: https://www.youtube.com/@artotalentChris DavisonLinkedIn: https://www.linkedin.com/in/chrisdavison155/Harry SloanLinkedIn: https://www.linkedin.com/in/harry-sloan-605620154/Timestamps:00:00 Introduction00:57 What Centrix does02:23 From pharmacist to CEO04:03 Big pharma to a small company05:16 Why launch Centrix now07:23 Partnership, not transactions09:41 The Integrated CMC Partnership12:28 Investing in data and growth15:05 What growth depends on18:12 How biotechs choose a partner19:09 Where AI fits today21:40 A year from now#MakingItInManufacturing #ARTOTalent #CPHI #CPHIMilan #CDMO #Biotech #CMC #DrugDevelopment Hosted on Acast. See acast.com/privacy for more information.
    Show More Show Less
    23 mins
  • CPHI Milan 2026: Capacity Is Not The Issue Anymore, It's Certainty - Katie Edgar and Sigma Mostafa
    Nov 13 2026
    Register your interest for 2027 here: https://www.cphi.com/europe/register-attend/?utm_source=partner&utm_medium=referral&utm_campaign=hln27cpw-cl-artoFive years ago, everybody was focused on capacity. For Katie Edgar and Sigma Mostafa of KBI Biopharma, capacity is not the issue anymore: what customers need is certainty, and it starts with planning for the problems before they happen.This week on Making It In Manufacturing, Elliot Payne sat down with Katie Edgar, Chief Business Officer, and Sigma Mostafa, Chief Scientific & Technology Officer at KBI Biopharma, at CPHI Milan 2026, where ARTO was the official podcast partner.In this episode, Katie and Sigma cover:(00:29) What KBI Biopharma does: an end-to-end CDMO in mammalian and microbial, from pre-clinical to commercial manufacturing, with four commercial products and 50 plus early stage molecules a year.(01:22) Katie's journey from strategy and law to leading business development as Chief Business Officer.(03:45) Why Katie calls herself a paid pessimist, and how setting expectations early gives customers certainty.(05:32) How the two work together, and their advice for anyone stepping into a C-suite role, especially women.(07:16) Sigma's journey at KBI, from building process development from the ground up to leading about 500 people.(09:09) Failing fast, learning fast, and taking accountability as a leader.(12:21) Whether it's getting better for women in the industry, and why a strategy to come back after time off matters.(13:25) What makes KBI a technical powerhouse but nimble, in its 30th anniversary year.(17:28) Scientific depth with commercial sense, and why the quality of the data is the differentiator.(21:10) Celebrating the wins, and KBI's monthly win room.(23:48) The one thing they would remove from pharma manufacturing.Watch the full episode to hear why Katie believes the market now wants certainty, not capacity.Follow ARTOLinkedIn: https://www.linkedin.com/company/artotalent/Spotify: https://open.spotify.com/show/1cSZVJ63yXJ3kqnVORyTbwInstagram: https://www.instagram.com/arto.talentTikTok: https://www.tiktok.com/@artotalentApple Podcasts: https://podcasts.apple.com/gb/podcast/making-it-in-manufacturing/id1819731245Website: https://arto-talent.com/Youtube: https://www.youtube.com/@artotalentKatie EdgarLinkedIn: [Katie Edgar LinkedIn]Sigma MostafaLinkedIn: [Sigma Mostafa LinkedIn]Elliot PayneLinkedIn: https://www.linkedin.com/in/elliot-payne-2a4a917a/Timestamps:00:00 Introduction00:29 What KBI Biopharma does01:22 Katie's journey03:45 The paid pessimist05:32 Stepping into the C-suite07:16 Growing with KBI09:09 Failing fast and accountability12:21 Women in the industry13:25 Technical powerhouse, but nimble17:28 Science, business and data21:10 Celebrating the wins23:48 One thing to remove from the industry#MakingItInManufacturing #ARTOTalent #CPHI #CPHIMilan #CDMO #Biologics #WomenInLeadership #Leadership Hosted on Acast. See acast.com/privacy for more information.
    Show More Show Less
    28 mins
  • CPHI Milan 2026: Can The Asset Deliver The Value? - Sven Remmerbach
    Nov 13 2026
    Register your interest for 2027 here: https://www.cphi.com/europe/register-attend/?utm_source=partner&utm_medium=referral&utm_campaign=hln27cpw-cl-artoWhen a private equity firm looks at a pharma manufacturing site, the financial analysis can tell it what happened. Sven Remmerbach, Managing Director of pharmBridge, answers the simpler question: can the asset deliver the value the investor is looking for?This week on Making It In Manufacturing, Elliot Payne sat down with Sven Remmerbach, Managing Director of pharmBridge, who ran two manufacturing sites at Baxter before moving into consulting, at CPHI Milan 2026, where ARTO was the official podcast partner.In this episode, Sven covers:(00:58) His path from pharmacy studies and a PhD, through internships in hospital and local pharmacies and in industry, into pharmaceutical manufacturing.(02:16) What pharmBridge offers: senior leaders and project experts who help pharma companies execute transformations, technology transfers and strategic investments.(02:45) Why he stayed at Baxter so long: learning in its contract manufacturing business, P&L responsibility, and a mission of serving patients.(04:13) His most rewarding period: the early days of contract manufacturing, on the front line with clients.(05:33) Advice for anyone stepping up to run large teams across sites: shared values, shared goals, smart KPIs and daily disciplines.(06:45) Whether leadership came naturally, and how he learned it from small teams upwards.(07:53) Moving from running sites to consulting, where nobody books your flights any more.(09:00) What pharmBridge does when a PE firm brings it in to look at a pharma manufacturing asset.(10:01) The one question PE firms should ask themselves before acquiring a site.(11:31) Whether he's enjoying it: faster decision cycles, and the freedom to just do things.(12:00) The one thing he would take out of pharma manufacturing.Watch the full episode to hear why Sven believes the organisation can matter more than the equipment.Follow ARTOLinkedIn: https://www.linkedin.com/company/artotalent/Spotify: https://open.spotify.com/show/1cSZVJ63yXJ3kqnVORyTbwInstagram: https://www.instagram.com/arto.talentTikTok: https://www.tiktok.com/@artotalentApple Podcasts: https://podcasts.apple.com/gb/podcast/making-it-in-manufacturing/id1819731245Website: https://arto-talent.com/Youtube: https://www.youtube.com/@artotalentSven RemmerbachLinkedIn: [Sven Remmerbach LinkedIn]Elliot PayneLinkedIn: https://www.linkedin.com/in/elliot-payne-2a4a917a/Timestamps:00:00 Introduction00:58 From pharmacy to manufacturing02:16 What pharmBridge offers02:45 Why he stayed at Baxter04:13 His most rewarding role05:33 Leading large teams across sites06:45 Learning to lead07:53 From site leader to consultant09:00 Working with PE firms10:01 One question for PE buyers11:31 Enjoying the freedom12:00 One thing to remove from the industry#MakingItInManufacturing #ARTOTalent #CPHI #CPHIMilan #PrivateEquity #Leadership #PharmaManufacturing #TechTransfer Hosted on Acast. See acast.com/privacy for more information.
    Show More Show Less
    14 mins
adbl_web_anon_alc_button_suppression_t1
No reviews yet